share_log

T2 Biosystems | PRE 14A: Preliminary proxy statements relating to merger or acquisition

T2 Biosystems | PRE 14A: Preliminary proxy statements relating to merger or acquisition

T2 Biosystems | PRE 14A:並購重組委托聲明
美股SEC公告 ·  11/09 06:05

牛牛AI助理已提取核心訊息

T2 Biosystems, Inc. (TTOO.US), a leader in the development of innovative medical diagnostic equipment, has announced the scheduling of its 2024 Annual Meeting of Stockholders to be held on December 30, 2024. The meeting will be conducted solely via live webcast, allowing stockholders to participate, vote, and submit questions online. The company has outlined several key proposals for the meeting, including the election of three directors, Laura Adams, Robin Toft, and Seymour Liebman, to serve until the 2027 annual meeting, the approval of the amendment and restatement of the 2014 Incentive Award Plan, and the ratification of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company is leveraging SEC rules that permit proxy materials to be furnished over the Internet, reducing environmental impact and printing costs. Stockholders of record as of November 5, 2024, are entitled to vote at the meeting. The company has emphasized the importance of stockholder votes, urging participation in the meeting or prompt voting by proxy.
T2 Biosystems, Inc. (TTOO.US), a leader in the development of innovative medical diagnostic equipment, has announced the scheduling of its 2024 Annual Meeting of Stockholders to be held on December 30, 2024. The meeting will be conducted solely via live webcast, allowing stockholders to participate, vote, and submit questions online. The company has outlined several key proposals for the meeting, including the election of three directors, Laura Adams, Robin Toft, and Seymour Liebman, to serve until the 2027 annual meeting, the approval of the amendment and restatement of the 2014 Incentive Award Plan, and the ratification of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company is leveraging SEC rules that permit proxy materials to be furnished over the Internet, reducing environmental impact and printing costs. Stockholders of record as of November 5, 2024, are entitled to vote at the meeting. The company has emphasized the importance of stockholder votes, urging participation in the meeting or prompt voting by proxy.
T2 Biosystems, Inc.(TTOO.US)是一家在創新醫療診斷設備開發中處於領先地位的公司,宣佈了其2024年股東年會的安排,定於2024年12月30日舉行。會議將完全通過現場網絡直播進行,股東可以在線參與、投票和提問。公司已經爲會議提出了幾個關鍵議案,包括選舉三名董事,Laura Adams、Robin Toft和Seymour Liebman,任期至2027年年會,批准修訂2014年激勵獎勵計劃,以及批准BDO USA,LLP爲截至2024年12月31日的財政年度獨立註冊會計師事務所。公司正在利用SEC規定允許通過互聯網提供代理材料,以減少環保影響和印刷成本。截至2024年11月5日持股記錄的股東有權在會議上投票。公司強調股東投票的重要性,敦促參加會議或及時通過代理進行投票。
T2 Biosystems, Inc.(TTOO.US)是一家在創新醫療診斷設備開發中處於領先地位的公司,宣佈了其2024年股東年會的安排,定於2024年12月30日舉行。會議將完全通過現場網絡直播進行,股東可以在線參與、投票和提問。公司已經爲會議提出了幾個關鍵議案,包括選舉三名董事,Laura Adams、Robin Toft和Seymour Liebman,任期至2027年年會,批准修訂2014年激勵獎勵計劃,以及批准BDO USA,LLP爲截至2024年12月31日的財政年度獨立註冊會計師事務所。公司正在利用SEC規定允許通過互聯網提供代理材料,以減少環保影響和印刷成本。截至2024年11月5日持股記錄的股東有權在會議上投票。公司強調股東投票的重要性,敦促參加會議或及時通過代理進行投票。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。